소아청소년기 이차성 골다공증 환자에서의 파미드로네이트 치료
Pamidronate Therapy in Children and Adolescents with Secondary Osteoporosis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose:The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis. Methods:Nine patients (7 males, 2 females, 13.2±2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86±0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle). Results:Underlying diseases were as follows; neurofibromatosis type 1 (n=2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n=2), hematologic malignancy (n=3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91±1.79 to 1.86±1.18, in L1-4 and -3.71±1.83 to -2.53±1.77 for femoral neck; P =0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P =0.008; phosphorus, P =0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47±1.69 years; range, 1.05 to 6.77 years). Conclusion:In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.
Abstract
Purpose:The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis. Methods:Nine patients (7 males, 2 females, 13.2±2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86±0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle). Results:Underlying diseases were as follows; neurofibromatosis type 1 (n=2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n=2), hematologic malignancy (n=3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91±1.79 to 1.86±1.18, in L1-4 and -3.71±1.83 to -2.53±1.77 for femoral neck; P =0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P =0.008; phosphorus, P =0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47±1.69 years; range, 1.05 to 6.77 years). Conclusion:In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.
참고문헌 (32)
- "Osteoporosis prevention, diagnosis, and therapy", NIH Consens Statement, 17, pp.1~45 (2000)
- Dent CE, "Keynote address: problems in metabolic bone disease, In Clinical aspects of metabolic bone diseases", pp.1~7 (1973), Excerpta Medica
- Bianchi ML, "Osteoporosis in children and adolescents", Bone, 41, pp.486~495 (2007)
- Tenbrock K, "Analysis of muscle strength and bone structure in children with renal disease", Pediatr Nephrol, 14, pp.669~672 (2000)
- Strauss AJ, "Bony morbidity in children treated for acute lymphoblastic leukemia", J Clin Oncol, 19, pp.3066~3072 (2001)
- Lettgen B, "Influence of steroid medication on bone mineral density in children with nephrotic syndrome", Pediatr Nephrol, 8, pp.667~670 (1994)
- Kotaniemi A, "Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis", Scand J Rheumatol, 28, pp.19~26 (1999)
- Halton JM, "Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia", J Bone Miner Res, 11, pp.1774~1783 (1996)
- Bachrach LK, "Clinical review 1: Bisphosphonate use in childhood osteoporosis", J Clin Endocrinol Metab, 94, pp.400~409 (2009)
- Ward L, "Bisphosphonate therapy for children and adolescents with secondary osteoporosis", Cochrane Database Syst Rev, (4), pp.CD005324~ (2007)
- Nishikawa M, "A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms", J Bone Miner Res, 13, pp.986~995 (1998)
- Phillipi CA, "Bisphosphonate therapy for osteogenesis imperfecta", Cochrane Database Syst Rev, (4), pp.CD005088~ (2008)
- 이지은, "신증후군 환아에서 스테로이드 유발 대사성 골질환에 대한 alendronate의 치료 효과", 대한소아신장학회지, 8(1), pp.33~42 (2004), 대한소아신장학회
- 임중섭, "수모세포종 치료후 발생한 척추골절에서 파미드로네이트 치료 1례", 대한소아내분비학회지, 12(1), pp.87~89 (2007), 대한소아내분비학회
- Lim JS, "Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents", J Clin Densitom, 13, pp.68~76 (2010)
- Lewiecki EM, "Official positions of the international society for clinical densitometry", J Clin Endocrinol Metab, 89, pp.3651~3655 (2004)
- "Diagnosis of osteoporosis in men, premenopausal women, and children", Writing Group for the ISCD Position Development Conference, 통권 : 7, pp.17~26 (2004)
- Daci E, "Mechanisms influencing bone metabolism in chronic illness", Horm Res, 58(1), pp.44~51 (2002)
- Brunetti-Pierri N, "Generalized metabolic bone disease in Neurofibromatosis type I", Mol Genet Metab, 94, pp.105~111 (2008)
- Schindeler A, "Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1)", Bone, 42, pp.616~622 (2008)
- Stevenson DA, "Bone mineral density in children and adolescents with neurofibromatosis type 1", J Pediatr, 150, pp.83~88 (2007)
- Duman O, "Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1", Brain Dev, 30, pp.584~588 (2008)
- Yilmaz K, "Bone mineral density in children with neurofibromatosis 1", Acta Paediatr, 96, pp.1220~1222 (2007)
- Amin S, "The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach", Arthritis Rheum, 42, pp.1740~1751 (1999)
- Homik JE, "A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis", J Rheumatol, 26, pp.1148~1157 (1999)
- Goldbloom EB, "Osteoporosis at presentation of childhood ALL: management with pamidronate", Pediatr Hematol Oncol, 22, pp.543~550 (2005)
- Geusens P, "Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy", J Clin Densitom, 4, pp.389~394 (2001)
- Steelman J, "Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions", J Pediatr, 142, pp.417~423 (2003)
- Acott PD, "Pamidronate treatment of pediatric fracture patients on chronic steroid therapy", Pediatr Nephrol, 20, pp.368~373 (2005)
- Henderson RC, "Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial", J Pediatr, 141, pp.644~651 (2002)
- Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta", N Engl J Med, 339, pp.947~952 (1998)
- Ott SM, "Long-term safety of bisphosphonates", J Clin Endocrinol Metab, 90, pp.1897~1899 (2005)